An Open-label Study Evaluating the Safety and Preliminary Clinical Activity of Cizutamig in Patients With Refractory Seropositive Rheumatoid Arthritis
Status: Recruiting
Location: See location...
Intervention Type: Drug, Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• 18 to 75 years old at the time of signing the informed consent form
• Diagnosis of adult-onset RA as defined by the 2010 ACR/EULAR classification criteria
• Moderately to severely active RA.
• Positive test results for RF and/or ACPA at Screening.
Locations
Other Locations
China
Wuhan Union Hospital
RECRUITING
Wuhan
Contact Information
Primary
Qiubai Li, Professor
qiubaili@hust.edu.cn
85726808
Backup
Di Wu
373181302@qq.com
18790696175
Time Frame
Start Date: 2025-06-23
Estimated Completion Date: 2027-06
Participants
Target number of participants: 28
Treatments
Experimental: Cizutamig
Related Therapeutic Areas
Sponsors
Leads: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology